Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?

MOspace/Manakin Repository

Breadcrumbs Navigation

Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/3046

[+] show full item record


Title: Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?
Author: Robertson, Sandy L.; Mayer, Jill Byerly
Keywords: antithrombotic
combination therapy
cardioembolic stroke
Date: 2004-07
Publisher: Family Physicians Inquiries Network
Citation: Journal of Family Practice, 53(7) 2004: 570+.
Abstract: Adjusted-dose warfarin (international normalized ratio [INR]=2.0-3.0) remains the most efficacious antithrombotic regimen for the primary and secondary prevention of cardioembolic stroke in high-risk patients with nonvalvular atrial fibrillation (NVAF) (strength of recommendation [SOR]: A, based on randomized controlled trials). Aspirin therapy at a dose of 75 to 325 mg reduces the risk of stroke to a lesser degree and may be useful for low-risk patients with NVAF or patients at high risk for bleeding (SOR: A, based on randomized controlled trials). Combination therapy with low, fixed-dose warfarin (1-2 mg) and aspirin has not been shown to be superior to aspirin therapy alone. Moreover, this combination appears to be inferior to adjusted-dose warfarin (SOR: A, based on randomized controlled trials). To date, no clinical trials have investigated the efficacy and safety of combining adjusted-dose warfarin and aspirin for the prevention of stroke from NVAF.
URI: http://hdl.handle.net/10355/3046

This item appears in the following Collection(s)

[+] show full item record